ArticleOncoimmunology

The novel agonistic iNKT-cell antibody NKT14m induces a therapeutic antitumor response against B-cell lymphoma.

Laura Escribà-Garcia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.